Where does PTC Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), PTC Therapeutics, Inc. ranks #3,355 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does PTC Therapeutics, Inc. hold?

PTC Therapeutics, Inc. holds 111 US utility patents granted between 2015 and 2025, spanning 20 technology areas.

What is PTC Therapeutics, Inc.'s Innovation Score?

PTC Therapeutics, Inc. has an Innovation Score of 46.0 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is PTC Therapeutics, Inc.'s patent grant rate increasing or decreasing?

PTC Therapeutics, Inc.'s recent grant velocity is +2% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for PTC Therapeutics, Inc.'s patents?

PTC Therapeutics, Inc.'s patents average 14.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the PTC Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

PTC Therapeutics, Inc.

Q: What technology areas does PTC Therapeutics, Inc. focus on?

PTC Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 90 patents. Grants appear in 20 CPC subclasses total.

USPTO PatentsView assignee record - 111 granted patents across 20 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, PTC ranks #3,355 of 49,997 tracked US assignees by granted-patent volume, with 111 patents across 20 technology areas.

#3,355
of 49,997 US assignees by volume: Top 22%
by Innovation Score (46.0/100): 14.5
avg claims per patent: +2%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3355 · US Corporation #3,355 · 111 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 111 grants
TOP-DECILE #3,355/49,997
PHOTO-FINISH Macneil IP
CPC-FOCUS A61P · 20 areas
INNOV-PAR 46.0/100
CLAIMS-RICH 14.5 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +2% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Macneil IP LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Ineos Europe · near

46
Pride Mobility… · near

46
PTC Therapeutics · this assignee

46
Pulse Secure · near

46
Radiometer Medical APS · near

46
3D Lighting… · lowest

7

What this shows PTC's Innovation Score is 46.0/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where PTC's grants concentrate

PTC Therapeutics, Inc. is a focused PatentsView assignee: 20 CPC subclasses with 81.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (16 grants) versus a trough of 5 in 2024. By volume, PTC sits between Macneil IP LLC and SCA Ipla Holdings Inc..

PTC's three-year grant acceleration

From 2019–2021 to 2022–2024, PTC Therapeutics, Inc. moved from 36 to 28 grants (0.78x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,905. See the growth leaderboard.

Macneil IP

111
Musc Foundation f…

111
Millerknoll

111
Neuropace

111
ROM

111
S V V Technology…

111
Sagemcom Energy &…

111
SCA Ipla Holdings

111
PTC Therapeutics ◀

111

What this shows PTC holds 111 patents at rank #3,355, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near PTC

By rank, the assignees closest to #3,355 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in PTC's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for PTC, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Pride Mobility Products Corporation 46 Ineos Europe AG 46 Pulse Secure, LLC 46 Radiometer Medical APS 46

Similar claim depth

Nearest assignees by average claims per patent (14.5 here).

Apollo Intelligent Driving Technology (BEIJING) Co., Ltd. 14.5 avg Radiant Opto-Electronics Corporation 14.5 avg Blue Cube IP LLC 14.5 avg The Hospital for Sick Children 14.5 avg

PTC's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

PTC Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	11	9.9%
2016	16	14.4%
2017	6	5.4%
2018	10	9.0%
2019	10	9.0%
2020	14	12.6%
2021	12	10.8%
2022	8	7.2%
2023	15	13.5%
2024	5	4.5%
2025partial year	4	3.6%

Which technologies does PTC Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 90

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 72

C07D - Heterocyclic Compounds 72

C07C - Acyclic OR Carbocyclic Compounds 15

Y02A - Technologies FOR Adaptation TO Climate Change 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 6

C07K - Peptides 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C12Y - Enzymes 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

Top 15 of 20 technology areas

Where it ranks

Overall rank by patents

#3,355

of 49,997 tracked assignees

Innovation Score

46.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

PTC Therapeutics, Inc.'s patent record in context - here's where to go next.

PTC Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 81.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #3,355 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare PTC Therapeutics, Inc. against Macneil IP LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.